Cargando…

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients

BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuerti, Sascha, Oliveira-Ferrer, Leticia, Milde-Langosch, Karin, Schmalfeldt, Barbara, Legler, Karen, Woelber, Linn, Prieske, Katharina, Mahner, Sven, Trillsch, Fabian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522140/
https://www.ncbi.nlm.nih.gov/pubmed/28591727
http://dx.doi.org/10.18632/oncotarget.17978
_version_ 1783252109671530496
author Kuerti, Sascha
Oliveira-Ferrer, Leticia
Milde-Langosch, Karin
Schmalfeldt, Barbara
Legler, Karen
Woelber, Linn
Prieske, Katharina
Mahner, Sven
Trillsch, Fabian
author_facet Kuerti, Sascha
Oliveira-Ferrer, Leticia
Milde-Langosch, Karin
Schmalfeldt, Barbara
Legler, Karen
Woelber, Linn
Prieske, Katharina
Mahner, Sven
Trillsch, Fabian
author_sort Kuerti, Sascha
collection PubMed
description BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tumour tissue of 100 patients with EOC was analysed for protein expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot analysis. Expression patterns in patients with ‘extensive intraperitoneal’ metastases (pT3c pN1 and pT3b-pT3c pN0, n=80) were compared to patients with ‘predominantly retroperitoneal’ metastases (pT1a-pT3b, pN1, n=20). Overall and progression-free survival was analysed by Kaplan-Meier method. RESULTS: While no significant differences in expression levels among the different modes of metastases were noted for VEGF-A and -D, VEGF-C expression was significantly higher in the group of predominantly retroperitoneal metastases compared to the group with extensive intraperitoneal metastases. Patients with high VEGF-C expression had a significantly worse overall survival compared to patients with low expression levels. CONCLUSIONS: Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. VEGF-C may serve as a molecular marker to identify patients with assumed high risk for lymphatic metastases, who might benefit from specific treatment strategies.
format Online
Article
Text
id pubmed-5522140
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55221402017-08-08 VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients Kuerti, Sascha Oliveira-Ferrer, Leticia Milde-Langosch, Karin Schmalfeldt, Barbara Legler, Karen Woelber, Linn Prieske, Katharina Mahner, Sven Trillsch, Fabian Oncotarget Research Paper BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tumour tissue of 100 patients with EOC was analysed for protein expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot analysis. Expression patterns in patients with ‘extensive intraperitoneal’ metastases (pT3c pN1 and pT3b-pT3c pN0, n=80) were compared to patients with ‘predominantly retroperitoneal’ metastases (pT1a-pT3b, pN1, n=20). Overall and progression-free survival was analysed by Kaplan-Meier method. RESULTS: While no significant differences in expression levels among the different modes of metastases were noted for VEGF-A and -D, VEGF-C expression was significantly higher in the group of predominantly retroperitoneal metastases compared to the group with extensive intraperitoneal metastases. Patients with high VEGF-C expression had a significantly worse overall survival compared to patients with low expression levels. CONCLUSIONS: Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. VEGF-C may serve as a molecular marker to identify patients with assumed high risk for lymphatic metastases, who might benefit from specific treatment strategies. Impact Journals LLC 2017-05-18 /pmc/articles/PMC5522140/ /pubmed/28591727 http://dx.doi.org/10.18632/oncotarget.17978 Text en Copyright: © 2017 Kuerti et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Kuerti, Sascha
Oliveira-Ferrer, Leticia
Milde-Langosch, Karin
Schmalfeldt, Barbara
Legler, Karen
Woelber, Linn
Prieske, Katharina
Mahner, Sven
Trillsch, Fabian
VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title_full VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title_fullStr VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title_full_unstemmed VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title_short VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
title_sort vegf-c expression attributes the risk for lymphatic metastases to ovarian cancer patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522140/
https://www.ncbi.nlm.nih.gov/pubmed/28591727
http://dx.doi.org/10.18632/oncotarget.17978
work_keys_str_mv AT kuertisascha vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT oliveiraferrerleticia vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT mildelangoschkarin vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT schmalfeldtbarbara vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT leglerkaren vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT woelberlinn vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT prieskekatharina vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT mahnersven vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients
AT trillschfabian vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients